Table 1.
All patients: 69 | % | Critical n: 27 | % | Severe n: 14 | % | Mild n: 28 | % | |
---|---|---|---|---|---|---|---|---|
Age [years] |
61 (24–90) |
- |
63 (39–79) |
- |
76 (31–90) |
- |
45 (24–65) |
- |
Female | 24 | 34.8 | 5 | 18.5 | 3 | 21.4 | 16 | 57.1 |
Male | 45 | 65.2 | 22 | 81.5 | 11 | 78.6 | 12 | 42.9 |
Comorbidities | ||||||||
Hypertension | 21 | 51.2 | 12 | 44.4 | 9 | 64.3 | n.a. | - |
Cardiovascular disease | 14 | 34.1 | 5 | 18.5 | 9 | 64.3 | n.a. | - |
Pulmonary disease | 6 | 14.6 | 2 | 7.4 | 4 | 28.6 | n.a. | - |
Chronic kidney disease | 6 | 14.6 | 1 | 3.7 | 5 | 35.7 | n.a. | - |
Diabetes | 10 | 24.4 | 6 | 22.2 | 4 | 28.6 | n.a. | - |
Malignancy | 8 | 19.5 | 4 | 14.8 | 4 | 28.6 | n.a. | - |
none | 6 | 14.6 | 6 | 22.2 | 0 | 0 | n.a. | - |
Diagnostic markers | ||||||||
Interleukin-6 [pg/ml] | 1012.8 | - |
1452.1 (3774.6) |
- |
46.1 (26.8) |
- | n.a. | - |
Procalcitonin [ng/ml] | 7 | - |
9.9 (21.9) |
- |
0.17 (0.11) |
- | n.a. | - |
C-reactive protein [mg/l] | 128.1 | - |
162.2 (75.8) |
- |
65.3 (47.1) |
- | n.a. | - |
Lactate dehydrogenase [U/l] | 800.97 | - |
1061.7 (1976.3) |
- |
305.6 (78.3) |
- | n.a. | - |
Complications | ||||||||
Bacterial superinfection | 16 | 39 | 11 | 40.7 | 5 | 35.7 | n.a. | - |
Treatment | ||||||||
Hydroxychloroquine, Ritonavir + Lopinavir (Kaletra) | 24 | 58.5 | 18 | 66.7 | 6 | 42.9 | n.a. | - |
Fatal outcome | ||||||||
Total | 11 | 26.8 | 10 | 37 | 1 | 7.1 | n.a. | - |
Patients were categorized as either severely (hospitalized on regular ward, requiring O2 supplementation, n = 14), critically (intensive care unit admission and in need of invasive mechanical ventilation, n = 27) or mildly diseased (non-hospitalized, n = 28). Diagnostic markers are depicted as mean and standard deviation (SD) (in brackets) of all analyzed laboratory parameters obtained 13–25 days post symptom onset for critically and severely diseased patients. Percentage [%] is indicated. n.a.: not available. Source data are provided as a Source Data file.